245 related articles for article (PubMed ID: 18649566)
41. Letter to the editor.
Ehrmann EH
Aust Endod J; 2010 Aug; 36(2):96. PubMed ID: 20666758
[No Abstract] [Full Text] [Related]
42. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?
Aragon-Ching JB; Dahut WL
Oncologist; 2008 Dec; 13(12):1314; author reply 1315. PubMed ID: 19088325
[No Abstract] [Full Text] [Related]
43. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm.
Malden N; Beltes C; Lopes V
Br Dent J; 2009 Jan; 206(2):93-8. PubMed ID: 19165270
[TBL] [Abstract][Full Text] [Related]
44. [Treatment with bisphosphonates and previous dental health].
Madrid C; Bouferrache K; Jaques B; Broome M
Rev Med Suisse; 2009 Apr; 5(200):909-10; author reply 910-1. PubMed ID: 19438092
[No Abstract] [Full Text] [Related]
45. Bisphosphonate osteonecrosis: a protocol for surgical management.
Markose G; Mackenzie FR; Currie WJ; Hislop WS
Br J Oral Maxillofac Surg; 2009 Jun; 47(4):294-7. PubMed ID: 19231046
[TBL] [Abstract][Full Text] [Related]
46. Osteonecrosis: what dentists need to know.
Thoman RD
Hawaii Dent J; 2006; 37(6):9-10, 12-3. PubMed ID: 17290948
[No Abstract] [Full Text] [Related]
47. A safe modality.
Kyrgidis A; Vahtsevanos K
Br Dent J; 2009 Jun; 206(11):561; author reply 562. PubMed ID: 19521357
[No Abstract] [Full Text] [Related]
48. Comment on the American Association of Oral and Maxillofacial Surgeons statement on bisphosphonates.
Zahrowski JJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1440-1. PubMed ID: 17577522
[No Abstract] [Full Text] [Related]
49. Horizons: the 2009 table clinics.
Thumbigeremath V
Northwest Dent; 2009; 88(3):33-4, 87. PubMed ID: 19691205
[No Abstract] [Full Text] [Related]
50. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
Carmagnola D; Celestino S; Abati S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
[TBL] [Abstract][Full Text] [Related]
51. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
Gallego L; Junquera L
Br J Oral Maxillofac Surg; 2009 Jan; 47(1):67-8. PubMed ID: 18639371
[TBL] [Abstract][Full Text] [Related]
52. Treating osteoporosis.
Smith G; Stassen L; Flint S
Ir Med J; 2009 Mar; 102(3):88; author reply 89. PubMed ID: 19489199
[No Abstract] [Full Text] [Related]
53. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
[No Abstract] [Full Text] [Related]
54. Specialists play down risk of jaw condition.
Stassen LF
J Ir Dent Assoc; 2008; 54(4):153. PubMed ID: 18780680
[No Abstract] [Full Text] [Related]
55. Dental implications of osteogenesis imperfecta: treatment with IV bisphosphonate: report of a case.
Milano M; Wright T; Loechner KJ
Pediatr Dent; 2011; 33(4):349-52. PubMed ID: 21903004
[TBL] [Abstract][Full Text] [Related]
56. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
Siddiqi A; Payne AG; Zafar S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
[TBL] [Abstract][Full Text] [Related]
57. Oral bisphosphonates and dental implants.
McLeod NM
J Oral Maxillofac Surg; 2009 Jun; 67(6):1355. PubMed ID: 19446233
[No Abstract] [Full Text] [Related]
58. The benefits and costs of bisphosphonates.
Coleman RE
J Support Oncol; 2007; 5(10):483-4. PubMed ID: 18240670
[No Abstract] [Full Text] [Related]
59. Do Fosamax-type drugs increase the risk of osteonecrosis of the jaw for patients receiving dental implants?
Wynn RL
Gen Dent; 2008; 56(5):410-1. PubMed ID: 18683394
[No Abstract] [Full Text] [Related]
60. Bisphosphonates and avascular necrosis of the jaws.
Carter GD; Goss AN
Aust Dent J; 2003 Dec; 48(4):268. PubMed ID: 14738134
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
